Services provided such as early and late stage product acquisitions, maximizing market share, and enhancing employee contributions to improve their products and services for their customers are key deliverables that Healthcare Economics will contribute to your firm to sustain a continuum of steady and consistent growth.

Product Candidate Acquisition: Early Stage

Contract manufacturing organizations (CMO) and academia are focused on conceptualizing and developing early stage product candidates that will eventually satisfy unmet medical needs.  Early stage product candidates are those products that have met and succeeded the proof of concept requirement and have been proven successfully in phase I studies.

At this stage commercial viability has yet to be proven due to the fact that many stages of development remain.  The opportunity to out-license an early stage product candidate to commercial firms is highly attractive for early stage developers and established commercial firms.

Developers seek revenue and partners in order to fulfill their mission of product development and sustained inflow of capital while biotech and pharma firms seek to supplant existing therapies at the end of their product life cycle with new and highly desirable candidates to capture market share and meet unmet medical needs. HCE with its experienced team and established networks will be instrumental in executing in-licensing, out-licensing, joint ventures, co-marketing, co-promotional, and cross licensing arrangements for business partners.

Product Candidate Acquisition: Late Stage

Many firms are interested in obtaining products in late stages of development.  As a point of reference products in late stages of development tend to be within and after phase II.  Typically firms choose to identify and select these product opportunities for a variety of reasons.

Paramount in the decision making process will be the likelihood that these products have a good chance to succeed and be launched within the designated markets where the firm has a competitive advantage.

CMO’s are keen to partner with established biotech & pharmaceutical firms and investment houses willing to in-license a product candidate in order to satisfy a research and development need as well as strengthening their existing pipeline.

Pharmaceutical and biotech firms may also realize synergy and seek to partner with each other in order to commercialize a product and capture a predefined market share. HCE with its experienced team and established networks will be instrumental in executing in-licensing, out-licensing, joint ventures, co-marketing, co-promotional, and cross licensing arrangements for willing partners.

PREMEDIA SERVICES: ADDRESSING BUSINESS COMMUNICATION NEEDS

Healthcare Economics  and Vakils Premedia are working together to introduce Vakils’ integrated premedia services for pharmaceutical, medical packaging firms, and all enterprises interested in expanding their communication footprint.  Vakils Premedia is a subsidiary of Vakil & Sons Pvt. Ltd. (Vakils) and has been a pioneer in the printing and publishing business for more than 66 years.

Vakils Premedia is a global provider of integrated premedia services for design and implementation of artwork and management services offering eDetailing, ePublishing, packaging, prepress, page composition, color management, data conversion, and cross media services aimed at addressing the firms’ business communication needs.

The company is equipped with best-in-class infrastructure and IT security systems. It is supported by professionals highly qualified in graphic design, software development and premedia technology. Vakils Premedia has all the modern encryption technologies and has complete data security as per ISO 27001:2013 standards. We have an experienced management team delivering IT and premedia services to customers in India, Australia, Europe, UK, USA and Asia.

PRECLINICAL RESEARCH SERVICES: IN BIOLOGY, ADMET-PK, PHARMACOLOGY, EXPLORATORY TOXICOLOGY, AND PROJECT MAMAGEMENT

Healthcare Economics  is partnering with TheraIndx offering differentiated services in Preclinical Research services in Biology, ADMET-PK, Pharmacology, Exploratory Toxicology and Project Management.

TheraIndx’s animal disease models play a vital role in the discovery and development of drugs, biologicals, herbals, and medical devices since they are generally a good predictor of efficacy and toxicity within humans and can be customized based upon research needs.  They are AAALAC accredited as well.

The firm offers a wide range of Animal disease models covering a variety of therapeutic areas such as Infection, Inflammation, Oncology, Diabetes, CNS, Obesity, Dyslipidemia, Arthritis, Medical devices and Wound healing.

In the current era of innovation in Lifesciences, be it drug discovery, biotechnology, medical devices or natural products, a key factor in translating an exciting idea to reality or evaluation of a newly designed molecule or product is to obtain robust and quality data from optimally designed experiments. We endeavor to meet these criteria.